| Molecular Formula | C30H30F2N6O3 |
| Molar Mass | 560.59 |
| Density | 1.36±0.1 g/cm3(Predicted) |
| Boling Point | 730.5±70.0 °C(Predicted) |
| Solubility | Soluble in DMSO |
| pKa | 6.52±0.35(Predicted) |
| Storage Condition | -20°C |
| Use | AMG-510 racemate are AMG-510 racemes. AMG-510 is an effective, orally bioavailable, selective covalent inhibitor of KRAS G12C with antitumor activity. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.784 ml | 8.919 ml | 17.838 ml |
| 5 mM | 0.357 ml | 1.784 ml | 3.568 ml |
| 10 mM | 0.178 ml | 0.892 ml | 1.784 ml |
| 5 mM | 0.036 ml | 0.178 ml | 0.357 ml |
| use | AMG-510 is a KRAS G12C inhibitor, which causes KRAS G12C tumor regression because it interrupts protein signaling. An effective, oral bioavailable, selective covalent inhibitor of KRAS G12C. AMG-510 is a potent KRAS G12C covalent inhibitor. AMG-510 selectively targets the KRAS p.G12C mutant, at either the DNA, RNA or protein level, and prevents, through an as of yet not elucidated manner, expression of and/or tumor cell signaling through the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. |
| biological activity | Sotorasib (AMG510) is racemate a racemate of AMG-510. AMG-510 is a potent covalent inhibitor of KRAS G12C with potential antitumor activity. |
| target | TargetValue KRAS G12Cv () |
| Target | Value |